MICHAEL CLOY: Open Payments
NPI 1447230263 · BROWNWOOD, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$662 in 32 payments from 15 companies in 2025. Trend: 2023 $441 · 2024 $313 · 2025 $662
Food & beverage: $632Long term medical supply or device loan: $30
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $195 |
| ABBVIE INC. | 4 | $85 |
| Novo Nordisk Inc | 5 | $76 |
| Exact Sciences Corporation | 3 | $48 |
| PFIZER INC. | 2 | $37 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $34 |
| Abbott Laboratories | 1 | $30 |
| Phathom Pharmaceuticals, Inc. | 3 | $27 |
| E.R. Squibb & Sons, L.L.C. | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
Products named: JARDIANCE, VRAYLAR, Cologuard Collection Kit, Ozempic, ELIQUIS, Kerendia, QULIPTA, Rybelsus.
Industry payments across TX — which companies pay providers there.
